Scienture Holdings, Inc. (NASDAQ:SCNX) Short Interest Update

Scienture Holdings, Inc. (NASDAQ:SCNX) saw a large decrease in short interest in August. As of August 31st, there was short interest totaling 1,022,272 shares, a decrease of 36.4% from the August 15th total of 1,607,698 shares. Approximately 3.2% of the shares of the stock are sold short. Based on an average daily volume of 400,597 shares, the days-to-cover ratio is currently 2.6 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Scienture stock. Susquehanna International Group LLP acquired a new stake in shares of Scienture Holdings, Inc. (NASDAQ:SCNX) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 235,117 shares of the company’s stock, valued at approximately $82,000. Susquehanna International Group LLP owned approximately 0.57% of Scienture as of its most recent SEC filing. Institutional investors and hedge funds own 5.68% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Scienture in a research note on Wednesday, June 24th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Scienture presently has a consensus rating of “Hold” and a consensus target price of $1.50.

Scienture Price Performance

NASDAQ:SCNX traded up $0.00 during trading hours on Friday, hitting $0.32. The company’s stock had a trading volume of 69,220 shares, compared to its average volume of 2,202,775. Scienture has a twelve month low of $0.24 and a twelve month high of $2.60. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.04 and a quick ratio of 2.97. The stock has a fifty day simple moving average of $0.39 and a 200-day simple moving average of $0.39. The company has a market capitalization of $13.06 million, a P/E ratio of -0.15 and a beta of 3.25.

Scienture (NASDAQ:SCNX) last posted its earnings results on Thursday, August 13th. The company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.02. The company had revenue of $0.34 million during the quarter, compared to the consensus estimate of $1.96 million.

Scienture Company Profile

Scienture Holdings, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for central nervous system and other underserved medical conditions. The company’s strategy centers on differentiated medicines designed to address unmet patient and caregiver needs, including alternative formulations and delivery options.

Scienture’s lead product is ONYDA XR (clonidine hydrochloride) extended-release oral suspension, a non-stimulant prescription treatment for attention-deficit/hyperactivity disorder (ADHD).